RxDoctor Payments Data

Cynthia Meyer, DO

Internal Medicine · Troy, PANPI 1487897864

Payments from drug & device makers

$518in general payments, 2019–2025

Across 12 payments — averaging $43.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$138
  • Biohaven Pharmaceuticals, Inc.$123
  • Novo Nordisk$98
  • Lilly USA, LLC$37
  • Boehringer Ingelheim$26
  • Alkermes, Inc.$26
  • plus $72 from 4 others

What the payments were for

  • Food & beverage$518100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$518 in reported general payments places this provider in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$312
Medicare patients
23
Services billed
60

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin21$21,022
Atorvastatin Calcium41$473
Albuterol Sulfate HfaAlbuterol Sulfate17$444
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen31$443
Clonazepam18$372
Trazodone Hcl15$371
Oxycodone Hcl12$316
Diclofenac Sodium12$232
Fluticasone Propionate22$222
Losartan Potassium15$207
Metoprolol Succinate15$206
Tizanidine Hcl15$204
Gabapentin19$202
Metformin Hcl17$189
Pregabalin11$164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$26$21,02221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Troy

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →